Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Grand Pharmaceutical Group Limited ( (HK:0512) ) has issued an announcement.
Grand Pharmaceutical Group Limited announced the completion of patient enrollment for its Phase III clinical trial of CBT-001, an innovative ophthalmic drug for treating pterygium. This milestone is significant for the company’s strategic focus on ophthalmology, as CBT-001 has shown promising results in earlier trials and addresses a major unmet need in pterygium treatment. The company holds exclusive rights to produce and commercialize CBT-001 in several regions, enhancing its competitive edge in the market. Additionally, Grand Pharmaceutical is expanding its innovative product pipeline and strengthening its marketing network to support sustainable growth.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited operates in the pharmaceutical industry, focusing on the development and commercialization of innovative ophthalmic drugs. The company is committed to advancing its position in the market by developing a range of products aimed at treating various eye conditions, including myopia, dry eye, and pterygium.
Average Trading Volume: 26,233,370
Technical Sentiment Signal: Buy
Current Market Cap: HK$30.99B
Find detailed analytics on 0512 stock on TipRanks’ Stock Analysis page.